Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

Cristina Calviño, Candela Ceballos, Ana Alfonso Piérola, Patricia Jáuregui, María Eréndira Calleja-Cervantes, Patxi San Martín‐Úriz, Paula Rodríguez-Márquez, Ángel Martín-Mallo, Elena Iglesias, Gloria Abizanda, Saray Rodríguez-Diaz, Rebeca Martínez-Turrillas, J.j. Illarramendi, María C. Viguria, Margarita Redondo, J. Rifón, Sara Villar, Juan José Lasarte, Susana Inogés, Ascensión López-Dı́az de Cerio, Mikel Hernáez, Felipe Prósper, Juan R. Rodríguez-MadozFrontiers in Immunology 2023 · DOI

TL;DR

Researchers have developed a high-efficiency, non-viral method to produce "off-the-shelf" (allogeneic) CAR-T cells for Acute Myeloid Leukemia (AML). By combining CRISPR-Cas9 gene editing with Sleeping Beauty transposon technology, they successfully created T cells that target the CD33 antigen while lacking the markers that typically trigger immune rejection or Graft-versus-Host Disease (GvHD).

What Problem Does This Paper Address?

Chimeric Antigen Receptor (CAR) T-cell therapy has revolutionized the treatment of certain B-cell cancers, but Acute Myeloid Leukemia (AML) remains a stubborn challenge. Most current CAR-T therapies are autologous, meaning they use a patient’s own T cells. However, T cells harvested from AML patients are often "exhausted" or dysfunctional due to the disease and intensive chemotherapy, leading to poor treatment outcomes.

Allogeneic (donor-derived) CAR-T cells offer a promising "off-the-shelf" alternative using healthy, fit T cells. The hurdle? Donor cells can attack the recipient (GvHD) or be quickly rejected by the recipient’s immune system. To make this work, scientists must "cloak" the cells by knocking out the T-cell receptor (TCR) and Human Leukocyte Antigen (HLA) complexes. Doing this efficiently, safely, and without expensive viral vectors is the core challenge this paper tackles.

Methods

The authors employed a sophisticated "one-step" engineering approach:

  • CRISPR-Cas9: Used as Ribonucleoprotein (RNP) complexes to knock out the TRAC (TCR) and B2M (HLA-I) genes. This prevents GvHD and reduces immune rejection.
  • Sleeping Beauty (SB) Transposon System: A non-viral gene transfer method. They used a minicircle DNA vector encoding a second-generation CAR targeting CD33 and an mRNA encoding the SB100X transposase. This system is generally cheaper and has a larger cargo capacity than traditional lentiviral vectors.
  • Phenotypic & Transcriptomic Profiling: The team performed deep characterization (flow cytometry and RNA-seq) comparing T cells from AML patients, young healthy donors, and senior healthy donors to understand why autologous therapies often fail.
  • In Vivo Testing: They used NSG mouse models (xenografts) to test the antitumoral efficacy of the engineered cells against human AML cells.

Datasets

The study utilized several primary sources and benchmarks:

  • Patient Cohort: Peripheral blood samples from 21 AML patients and 10 healthy controls (5 young, 5 senior).
  • Cell Lines: MOLM-13 (AML cell line), Jurkat-TPR (reporter cells), and HEK293T (for vector production).
  • Genomic Data: Integration site analysis was performed using the INSPIIRED pipeline, and CRISPR off-target effects were analyzed via iGUIDE.
  • Transcriptomics: RNA-sequencing data was used to map the "exhaustion" signatures of patient-derived cells.

Key Insights and Ideas

  • The "Fitness" Gap: T cells from AML patients are fundamentally different from healthy donor cells. They display a predominantly "effector" phenotype with high levels of exhaustion markers (PD1, LAG3) and activation markers (CD69, HLA-DR). This explains why patient-derived CAR-T cells often underperform in clinical trials.
  • Non-Viral Efficiency: The study proves that Sleeping Beauty transposons can be combined with CRISPR in a single electroporation step to achieve high-purity (>98% double-negative for HLA/TCR after selection) without compromising cell viability or expansion.
  • Safe Integration: Unlike some viral vectors that prefer integrating near active genes (potentially causing cancer), the Sleeping Beauty system showed a safe integration profile, preferring AT-rich distal intergenic regions with no preference for promoters or exons.
  • Scalability: The protocol was successfully scaled up to produce over 300 million edited CAR-T cells, a threshold necessary for clinical application.

Key Results

  • Phenotype: Healthy donor T cells maintained a "memory" phenotype, which is crucial for long-term persistence and efficacy in the body, whereas AML patient cells were skewed toward a short-lived "effector" state.
  • Efficacy: The CRISPR-edited allogeneic CAR-T cells showed equivalent in vitro and in vivo antitumoral activity compared to non-edited CAR-T cells.
  • Purity: After a simple magnetic selection step, the researchers achieved a nearly pure population of $HLA-I^{KO}/TCR^{KO}$ cells.
  • Off-target Safety: iGUIDE analysis confirmed that the CRISPR editing was highly specific to the B2M and TRAC loci, with no significant off-target mutations detected.

Limitations and Future Work

  • CD33 Specificity: While CD33 is a great target for AML, it is also expressed on healthy myeloid cells. The authors acknowledge that long-term persistence of these CAR-T cells could lead to prolonged myelosuppression (depletion of healthy blood cells).
  • Chromosomal Rearrangements: While the study found no significant off-target mutations, the authors note that simultaneous double-strand breaks at two loci (TCR and B2M) can theoretically lead to chromosomal translocations. Future work using "base editing" or "prime editing" (which don't require double-strand breaks) might mitigate this risk.
  • Clinical Translation: The study was performed in a lab setting. The next step is moving this "optimized protocol" into a GMP-compliant (Good Manufacturing Practice) facility for human clinical trials.

Summary updated

Abstract

Despite the potential of CAR-T therapies for hematological malignancies, their efficacy in patients with relapse and refractory Acute Myeloid Leukemia has been limited. The aim of our study has been to develop and manufacture a CAR-T cell product that addresses some of the current limitations. We initially compared the phenotype of T cells from AML patients and healthy young and elderly controls. This analysis showed that T cells from AML patients displayed a predominantly effector phenotype, with increased expression of activation (CD69 and HLA-DR) and exhaustion markers (PD1 and LAG3), in contrast to the enriched memory phenotype observed in healthy donors. This differentiated and more exhausted phenotype was also observed, and corroborated by transcriptomic analyses, in CAR-T cells from AML patients engineered with an optimized CAR construct targeting CD33, resulting in a decreased <i>in vivo</i> antitumoral efficacy evaluated in xenograft AML models. To overcome some of these limitations we have combined CRISPR-based genome editing technologies with virus-free gene-transfer strategies using <i>Sleeping Beauty</i> transposons, to generate CAR-T cells depleted of HLA-I and TCR complexes (HLA-I<sup>KO</sup>/TCR<sup>KO</sup> CAR-T cells) for allogeneic approaches. Our optimized protocol allows one-step generation of edited CAR-T cells that show a similar phenotypic profile to non-edited CAR-T cells, with equivalent <i>in vitro</i> and <i>in vivo</i> antitumoral efficacy. Moreover, genomic analysis of edited CAR-T cells revealed a safe integration profile of the vector, with no preferences for specific genomic regions, with highly specific editing of the HLA-I and TCR, without significant off-target sites. Finally, the production of edited CAR-T cells at a larger scale allowed the generation and selection of enough HLA-I<sup>KO</sup>/TCR<sup>KO</sup> CAR-T cells that would be compatible with clinical applications. In summary, our results demonstrate that CAR-T cells from AML patients, although functional, present phenotypic and functional features that could compromise their antitumoral efficacy, compared to CAR-T cells from healthy donors. The combination of CRISPR technologies with transposon-based delivery strategies allows the generation of HLA-I<sup>KO</sup>/TCR<sup>KO</sup> CAR-T cells, compatible with allogeneic approaches, that would represent a promising option for AML treatment.
BibTeX
@inproceedings{calvino2023optimization,
  author = {Cristina Calviño and Candela Ceballos and Ana Alfonso Piérola and Patricia Jáuregui and María Eréndira Calleja-Cervantes and Patxi San Martín‐Úriz and Paula Rodríguez-Márquez and Ángel Martín-Mallo and Elena Iglesias and Gloria Abizanda and Saray Rodríguez-Diaz and Rebeca Martínez-Turrillas and J.J. Illarramendi and María C. Viguria and Margarita Redondo and J. Rifón and Sara Villar and Juan José Lasarte and Susana Inogés and Ascensión López-Dı́az de Cerio and Mikel Hernáez and Felipe Prósper and Juan R. Rodríguez-Madoz},
  title = {{Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia}},
  booktitle = {Frontiers in Immunology},
  year = {2023},
  doi = {10.3389/fimmu.2023.1270843},
}
Figure